Federal Trade Commission v. Boehringer Ingelheim Pharmaceuticals, Inc.

778 F.3d 142, 414 U.S. App. D.C. 188, 90 Fed. R. Serv. 3d 1415, 114 U.S.P.Q. 2d (BNA) 1017, 2015 U.S. App. LEXIS 2559
CourtCourt of Appeals for the D.C. Circuit
DecidedFebruary 20, 2015
Docket12-5393
StatusPublished
Cited by80 cases

This text of 778 F.3d 142 (Federal Trade Commission v. Boehringer Ingelheim Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the D.C. Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Federal Trade Commission v. Boehringer Ingelheim Pharmaceuticals, Inc., 778 F.3d 142, 414 U.S. App. D.C. 188, 90 Fed. R. Serv. 3d 1415, 114 U.S.P.Q. 2d (BNA) 1017, 2015 U.S. App. LEXIS 2559 (D.C. Cir. 2015).

Opinion

Opinion for the Court filed by Circuit Judge WILKINS.

WILKINS, Circuit Judge:

In 2009, the Federal Trade Commission initiated an antitrust investigation into a patent settlement agreement between Boehringer Ingelheim Pharmaceuticals, Inc. (“Boehringer”), a brand-name pharmaceutical company, and Barr Industries (“Barr”), a generic drug manufacturer. As part of its investigation, the FTC issued an administrative subpoena seeking various documents relating to the settlement. When Boehringer failed to comply, the FTC initiated an enforcement proceeding in the District Court for the District of Columbia. See FTC v. Boehringer Ingelheim Pharm., Inc., 286 F.R.D. 101 (D.D.C.2012). Athough Boehringer ultimately certified compliance with the subpoena, it withheld hundreds of responsive documents under the work product doctrine and the attorney-client privilege. Ater the FTC objected, the District Court reviewed in camera a sample of the contested documents, and found that almost all *146 were properly withheld under the work product doctrine or the attorney-client privilege. On appeal, the FTC challenges the District Court’s application of the work product doctrine.

The FTC first asserts that the District Court erred as a matter of law when it concluded that settlement documents pertaining to a co-promotion agreement between Boehringer and Barr were prepared “in anticipation of litigation,” as required under the work product doctrine. According to the FTC, this conclusion cannot be reconciled with Boehringer’s representation that the co-promotion agreement involved payment for other services apart from Barr’s agreement to dismiss the patent litigation. We reject the FTC’s argument and hold that a settlement term may have independent economic value and still be considered part of a settlement for purposes of work product protection. In addition, we find that the District Court reasonably concluded that the bulk of the contested co-promotion materials were prepared “in anticipation” of the Boehringer-Barr litigation. The sole exception is a small group of documents drafted after the settlement was executed, which the District Court did not explicitly address.. Accordingly, we generally affirm the District Court’s findings on this issue but remand for further consideration with respect to the post-settlement documents.

The FTC next argues that the District Court committed legal error by applying an overly expansive definition of “opinion” work product, which is highly protected, as opposed to “fact” work product, which is substantially less so. Because we agree that the District Court misapprehended the proper distinction between fact and opinion work product, we reverse and remand on this issue.

I.

Boehringer manufactures Aggrenox and Mirapex, two patented pharmaceutical drugs that earn hundreds of millions of dollars in U.S. sales each year. In 2005, Barr sought and received FDA approval to market generic versions of these drugs, which led Boehringer to sue Barr for patent infringement. See Boehringer Ingelheim Int’l GmbH v. Barr Labs. Inc., Civ. Action No. 05-700-JJF (D. Del. filed Sept. 26, 2005). Barr, in turn, contended that Boehringer’s patents were invalid. While the Delaware litigation was pending, Boeh-ringer and Barr entered into settlement negotiations. Boehringer’s senior vice president and general counsel, Marla Per-sky, served as its lead negotiator during these discussions. FTC Investig. Hr’g Tr. at 70-71, J.A. 755-56. To this end, Persky and her staff engaged in both legal and business activities, including evaluating possible litigation outcomes, considering potential antitrust concerns, and evaluating and negotiating the business terms of the settlement. Id. at 113-16, 118, 120-23, J.A. 772-80.

On August 11, 2008, the two companies settled their dispute on the following terms: Barr would refrain from marketing its generic versions of Aggrenox and Mira-pex in the immediate future, but Boehringer would permit Barr to enter the market several months ahead of the expiration of Boehringer’s patents. Boehringer, 286 F.R.D. at 105; see also Aggrenox Settlement Agreement, J.A. 871-83; Press Release, J.A. 886-88. In the meantime, under a related co-promotion agreement, Barr would help Boehringer promote Ag-grenox to medical professionals in exchange for certain specified fees and royalties on Aggrenox sales. Boehringer, 286 F.R.D. at 105; see also Co-Promotion Agreement, J.A. 889-930.

*147 While this type of settlement deal is not necessarily unlawful, see FTC v. Actavis, Inc., — U.S. -, 133 S.Ct. 2223, 2237-38, 186 L.Ed.2d 343 (2013), such a settlement may be subject to antitrust scrutiny if it appears that the patent-holding firm— here, Boehringer- — was using the co-promotion agreement as a vehicle to avoid legitimate competition. Id. at 2236-37. And, indeed, the specific terms of this settlement raised the suspicions of the FTC that Boehringer was simply paying Barr off in order to delay the entry of generics into the market. Boehringer, 286 F.R.D. at 105. The FTC initiated an investigation and served Boehringer with a subpoena duces tecum. Id. After Boeh-ringer failed to meet a deadline for production, the FTC filed a petition in district court for an order enforcing the subpoena. Id.

Boehringer ultimately completed production and certified compliance with the subpoena, although it withheld nearly a quarter of identified responsive documents as protected by the attorney-client privilege, the work product doctrine, or both. Id. at 106. The FTC was not satisfied with Boehringer’s response and objected that many of the withheld documents fell outside the scope of these privileges. Id. It specifically challenged Boehringer’s refusal to produce documents containing financial analyses of the Aggrenox co-promotion agreement, forecasting analyses of alternative time lines for generic entry into the market, and financial analyses of the business terms of the settlement agreement. Id. at 108. The FTC also challenged Boehringer’s withholding of several other categories of documents not at issue in this appeal. See id. at 112 (discussing emails, notes, and reports on strategic decisions and other issues; emails containing legal advice or requests for legal advice; transmittal emails; and duplicate documents); Appellant’s Br. 12-16 (limiting challenge on appeal to financial documents analyzing litigation settlement and co-promotion agreement).

By agreement of the parties, Boehringer submitted a sample set of documents in camera to the District Court. Boehringer, 286 F.R.D. at 106. After reviewing the documents, the District Court issued a decision largely upholding Boehringer’s work product claims. Id. at 108-12.

The District Court first explained why the financial analyses and forecasts fell within the scope of the work product doctrine. It began by observing that work product developed for the purpose of settling a lawsuit falls within the scope of materials prepared “in anticipation of litigation,” as required under Rule 26. Boehringer, 286 F.R.D. at 107, 109;

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
778 F.3d 142, 414 U.S. App. D.C. 188, 90 Fed. R. Serv. 3d 1415, 114 U.S.P.Q. 2d (BNA) 1017, 2015 U.S. App. LEXIS 2559, Counsel Stack Legal Research, https://law.counselstack.com/opinion/federal-trade-commission-v-boehringer-ingelheim-pharmaceuticals-inc-cadc-2015.